Our hypothesis is corroborated by previous studies reporting the in vitro sensitivity of APL blasts to BCL-2 inhibitors and the therapeutical efficacy of VTX in relapsed/resistant APL patients [47, 60]. Here, BCL2 is linked to acute promyelocytic leukemia.